Dr. Anique Ducharme
Claim this profileMontreal Heart Institute
Studies Heart Failure
Studies Chronic Heart Failure
5 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Anique Ducharme is currently running
Heart Surgery
for Coronary Artery Disease
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Recruiting1 award N/A4 criteria
Tacrolimus
for Delayed Graft Function
The investigators hypothesize that preconditioning neurologically deceased organ donors with the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival without causing harm. Organ donors will be randomized to receive either 0.02 mg/kg ideal body weight (IBW) of tacrolimus single infusion or placebo before organ recovery. All corresponding recipients are enrolled and data is collected up to 7 days post-transplant to determine graft function and at 1 year to collect outcomes of vital status, re-transplantation and dialysis. The CINERGY Pilot Trial assesses feasibility for the main trial.
Recruiting2 awards Phase 26 criteria
More about Anique Ducharme
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Anique Ducharme has experience with
- CardioMems
- AI Echocardiogram
- Electrocardiogram
- NT-proBNP
- Revascularization By CABG
- Revascularization By PCI
Breakdown of trials Anique Ducharme has run
Heart Failure
Chronic Heart Failure
Coronary Artery Disease
Cardiomyopathy
Ischemia Reperfusion Injury
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anique Ducharme specialize in?
Anique Ducharme focuses on Heart Failure and Chronic Heart Failure. In particular, much of their work with Heart Failure has involved treating patients, or patients who are undergoing treatment.
Is Anique Ducharme currently recruiting for clinical trials?
Yes, Anique Ducharme is currently recruiting for 5 clinical trials in Montréal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Anique Ducharme has studied deeply?
Yes, Anique Ducharme has studied treatments such as CardioMems, AI echocardiogram, Electrocardiogram.
What is the best way to schedule an appointment with Anique Ducharme?
Apply for one of the trials that Anique Ducharme is conducting.
What is the office address of Anique Ducharme?
The office of Anique Ducharme is located at: Montreal Heart Institute, Montréal, Quebec H1T 1C8 Canada. This is the address for their practice at the Montreal Heart Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.